ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

IPSC vs SABS // 10Y YIELD & FRED MACRO BETA

Century Therapeutics Inc. (NASDAQ) VS. SAB Biotherapeutics Inc. (NASDAQ) • 15-METRIC TALLY: IPSC 1 — SABS 3
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (IPSC VS. SABS) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC IPSC SABS SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -14.10% -27.40% +13.30 IPSC /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield — -15.55% — TIE /fcf-yield <GO>
Operating Margin -15.80% — — TIE /operating-margins <GO>
Net Profit Margin -8.80% — — TIE /net-margins <GO>
Revenue Growth (YoY) 180.00% — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 0.20 7.07 -6.87 SABS /balance-sheet <GO>
Piotroski F-Score Quality 3/9 3/9 0.00 TIE /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 44.7 60.2 -15.45 SABS /rsi-technicals <GO>
10Y Yield & FRED Macro Beta ACTIVE — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — 20.6x — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $264.4M $293.9M -$29.5M SABS /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR IPSC REV SABS REV IPSC GROSS % SABS GROSS % IPSC FCF SABS FCF
FY 2025 $109.2M $0 — — -$104.7M -$45.7M
FY 2024 $6.6M $1.3M — — -$110.3M -$34.6M
FY 2023 $2.2M $2.2M — — -$88.3M -$25.1M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
IPSC // BETA —
SABS // BETA —